Table 1.
Patient characteristics by Hgb in Month 1 after starting HD, restricted to patients with Hgb ≥10.0 g/dL in Month 4 after starting HD
| Patient characteristic | All | Hgb (g/dL) in Month 1 after HD start |
||||
|---|---|---|---|---|---|---|
| <8.0 | 8.0–8.9 | 9.0–9.9 | 10.0–10.9 | ≥11.0 | ||
| Patients, n (%) | 4604 | 283 (6) | 822 (18) | 1260 (28) | 1209 (27) | 897 (20) |
| Baseline characteristics and treatments | ||||||
| Age (years) | 64.1 ± 14.5 | 59.2 ± 16.1 | 62.7 ± 14.9 | 64.4 ± 14.7 | 65.1 ± 14.2 | 64.9 ± 13.7 |
| Sex (% male) | 60 | 56 | 60 | 57 | 60 | 66 |
| Post-dialysis weight (kg) | 80.4 ± 22.8 | 75.9 ± 22.9 | 78.3 ± 22.1 | 80.7 ± 23.3 | 80.6 ± 21.3 | 81.8 ± 23.5 |
| BMI (kg/m2) | 28.1 ± 6.9 | 26.8 ± 6.3 | 27.2 ± 6.5 | 28.4 ± 7.2 | 28.3 ± 6.6 | 28.4 ± 7.0 |
| Catheter use (%) | 59 | 65 | 63 | 60 | 59 | 51 |
| Hemodiafiltration (%) | 3 | 2 | 3 | 3 | 3 | 4 |
| Single pool Kt/V | 1.33 ± 0.35 | 1.28 ± 0.37 | 1.33 ± 0.37 | 1.35 ± 0.35 | 1.33 ± 0.35 | 1.33 ± 0.35 |
| Laboratory values <30 days after starting HD | ||||||
| Hgb (g/dL) | 9.9 ± 1.3 | 7.4 ± 0.5 | 8.5 ± 0.3 | 9.5 ± 0.3 | 10.4 ± 0.3 | 11.8 ± 0.8 |
| TSAT (%) | 20.5 ± 9.8 | 18.9 ± 9.3 | 19.4 ± 10.1 | 20.2 ± 9.5 | 20.4 ± 9.4 | 22.6 ± 10.2 |
| Ferritin (ng/mL) | 337 ± 334 | 402 ± 365 | 366 ± 368 | 336 ± 325 | 331 ± 333 | 305 ± 305 |
| Serum albumin (g/dL) | 3.4 ± 0.5 | 3.1 ± 0.5 | 3.3 ± 0.6 | 3.4 ± 0.5 | 3.5 ± 0.5 | 3.6 ± 0.5 |
| Serum phosphorus (mg/dL) | 4.7 ± 1.5 | 5.0 ± 2.0 | 4.7 ± 1.5 | 4.6 ± 1.4 | 4.6 ± 1.4 | 4.8 ± 1.5 |
| Laboratory values 91–120 days after starting HD | ||||||
| Hgb (g/dL) | 11.5 ± 1.0 | 11.3 ± 1.0 | 11.5 ± 1.0 | 11.4 ± 1.0 | 11.4 ± 0.9 | 11.6 ± 1.1 |
| TSAT (%) | 26.6 ± 11.7 | 26.6 ± 12.5 | 25.7 ± 12.4 | 26.4 ± 11.4 | 26.7 ± 11.4 | 28.0 ± 11.9 |
| Ferritin (ng/mL) | 428 ± 377 | 388 ± 361 | 402 ± 352 | 439 ± 398 | 454 ± 372 | 424 ± 398 |
| Serum albumin (g/dL) | 3.7 ± 0.4 | 3.6 ± 0.5 | 3.6 ± 0.5 | 3.6 ± 0.5 | 3.7 ± 0.4 | 3.7 ± 0.4 |
| Serum phosphorus (mg/dL) | 5.2 ± 1.5 | 5.5 ± 1.6 | 5.4 ± 1.7 | 5.2 ± 1.5 | 5.2 ± 1.4 | 4.9 ± 1.3 |
| Anemia treatment during first 3 months of HD | ||||||
| ESA use (%, any during 3 months) | 92 | 98 | 98 | 98 | 91 | 77 |
| ESA dose (1000 U/week) | 12.7 ± 10.4 | 19.6 ± 13.6 | 16.7 ± 11.0 | 13.8 ± 10.1 | 10.8 ± 8.3 | 8.0 ± 8.9 |
| IV iron use (%, any during 3 months) | 86 | 86 | 87 | 87 | 86 | 82 |
| IV iron dose (mg/month) | 416 ± 292 | 445 ± 308 | 449 ± 301 | 428 ± 286 | 412 ± 281 | 364 ± 291 |
| Comorbid conditions (%) | ||||||
| Diabetes | 62 | 60 | 61 | 63 | 63 | 59 |
| Hypertension | 87 | 87 | 88 | 85 | 88 | 88 |
| CHF | 27 | 25 | 25 | 30 | 27 | 26 |
| PVD | 16 | 16 | 14 | 18 | 16 | 17 |
| Cancer (non-skin) | 11 | 9 | 12 | 12 | 12 | 9 |
Mean ± standard deviation or % shown; mean ESA and IV iron doses averaged >3 months and treat nonusers as 0 dose; note columns do not sum to the total due to 133 (3%) patients missing Month 1 Hgb data.